Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Heavy Cash Burn • Persistent Losses RLAY's strong liquidity and low leverage provide runway, but severe losses, negative cash flow, dilution risk, and demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights: • Holding key support • Recovery stalled • Breakout threshold Support Level: $18.38–$18.51 Resistance Level: $19.42–$19.46 RLAY is range-bound with a slight bearish bias last month; watch $18.38–$18.51 support, with a sustained move above $19.42–$19.46 needed to improve the outlook.
Sentiment & News
Key News Insights: • New fund stakes • Investor conference outreach • CFO share sale Relay Therapeutics drew new institutional investment and boosted investor outreach, though CFO selling and one fund's reduced stake create mixed sentiment.
AI Summary
Relay is now a well-funded, late-stage zovegalisib execution story: its cash runway into 2029 supports multiple registrational paths, but the investment case hinges on randomized pivotal confirmation of differentiated efficacy versus competitors, particularly in second-line HR+/HER2− breast cancer. Investors should view current valuation as vulnerable unless upcoming trials validate the promising cross-study data and regulatory plans remain on schedule.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Closed | +12.2% |